Viewing Study NCT00318656

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:33 PM
Ignite Modification Date: 2026-04-23 @ 1:05 PM
Study NCT ID: NCT00318656
Status: COMPLETED
Last Update Posted: 2009-05-07
First Post: 2006-04-25
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Insulin-Dependent Diabetes Mellitus View
Keywords:

Keywords

Keyword Brief Keyword Text View
None type 2 diabetes View
None rosiglitazone View
None metformin View
None glimepiride View
None glycemia View